Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Breast 1

Conditions

Breast Neoplasms 107Carcinoma, Renal Cell 74Neoplasm Metastasis 48Neoplasms 37Neuroendocrine Tumors 35Kidney Neoplasms 27Recurrence 19Tuberous Sclerosis 18Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 16Triple Negative Breast Neoplasms 15Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Head and Neck Neoplasms 14Glioblastoma 14Carcinoma, Hepatocellular 14Colorectal Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Brain Neoplasms 12Sarcoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Glioma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Carcinoma, Neuroendocrine 10

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 30Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Radiotherapy 16Pemetrexed 15Albumin-Bound Paclitaxel 15Nivolumab 13Ramucirumab 11Cyclophosphamide 11Drug Therapy 9Trastuzumab 8Erlotinib Hydrochloride 8zolbetuximab 7Taxes 7Radiosurgery 7trastuzumab deruxtecan 6cemiplimab 6Blood Specimen Collection 6regorafenib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Adenocarcinoma × Everolimus × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01784861 2021-07-08

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Washington University School of Medicine

Phase 1/2 Terminated
23 enrolled 17 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

NCT00688753 2016-09-02

MACS0460

Novartis

Phase 2 Completed
92 enrolled 12 charts
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

NCT00597506 2012-12-27

BEV/EV

Duke University

Phase 2 Completed
50 enrolled 7 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡